Skip to main content
Figure 6 | Cancer Cell International

Figure 6

From: Sensitization of U937 leukemia cells to doxorubicin by the MG132 proteasome inhibitor induces an increase in apoptosis by suppressing NF-kappa B and mitochondrial membrane potential loss

Figure 6

Determination of phosphorylated p65 (NF-кB subunit), Bcl-2 and bcl-XL in U937 human leukemic cells treated in vitro with Doxorubicin (DOX), the MG132 proteasome inhibitor, and MG132 + DOX. U937 cells were incubated, alone or in combination, with DOX 1 μM, MG132 (1 μM), or MG132 + DOX. After 1 h, the cells were harvested and the phosphorylated p65 protein was determined by flow cytometry (a). U937 were treated with MG132, DOX or it´s combination after that the cells were harvested and the Bcl-2 (b) and Bcl-XL (c) antiapoptotic proteins were determined by flow cytometry. An appropriate isotype control was utilized to adjust background fluorescence. The graphs show the Mean fluorescence intensity (MFI) of p65, Bcl-2 or Bcl-XL. For each sample, at least 20,000 events were acquired in a FACSAria-I cell sorter and the data were analyzed with FACSDiva software. Results represent the mean ± the Standard deviation (SD) of three independent experiments carried out in triplicate. p <0.05 DOX vs the Untreated control group (UCG); *p <0.05 MG132 + DOX or MG132 vs DOX or the UCG.

Back to article page